Abstract
Pyrazolic compounds represent a large source of anticancer compounds, based on the choice of the scaffold structure, the nature of the substituents and the sites of coordination. Here, we discuss our recent progresses in identifying new active molecules from a synthetic library of 14 nitrogen compounds. All these compounds exert antiproliferative activity against breast and colorectal cancer cell lines with varying IC50 values (the half-maximal inhibitory concentration, which is a measure of the effectiveness of a compound in inhibiting biological or biochemical function). We found a onelog order difference in activity among the different tested compounds. The most active compound 7 showed an IC50 values equal to 8.5µg/ml in both MDA-MB 231(breast cancer) and LOVO (colorectal cancer) cell lines.
Keywords: Anti-cancer, LOVO, MDA-MB231, MTT assay, Normoxie conditions and drug design, Pyrazole.
Letters in Drug Design & Discovery
Title:Library of Synthetic Compounds Based on Pyrazole Unit: Design and Screening Against Breast and Colorectal Cancer
Volume: 11 Issue: 8
Author(s): Farid Abrigach, Mohamed Khoutoul, Noureddine Benchat, Smaail Radi, Nihed Draoui, Olivier Feron, Olivier Riant and Rachid Touzani
Affiliation:
Keywords: Anti-cancer, LOVO, MDA-MB231, MTT assay, Normoxie conditions and drug design, Pyrazole.
Abstract: Pyrazolic compounds represent a large source of anticancer compounds, based on the choice of the scaffold structure, the nature of the substituents and the sites of coordination. Here, we discuss our recent progresses in identifying new active molecules from a synthetic library of 14 nitrogen compounds. All these compounds exert antiproliferative activity against breast and colorectal cancer cell lines with varying IC50 values (the half-maximal inhibitory concentration, which is a measure of the effectiveness of a compound in inhibiting biological or biochemical function). We found a onelog order difference in activity among the different tested compounds. The most active compound 7 showed an IC50 values equal to 8.5µg/ml in both MDA-MB 231(breast cancer) and LOVO (colorectal cancer) cell lines.
Export Options
About this article
Cite this article as:
Abrigach Farid, Khoutoul Mohamed, Benchat Noureddine, Radi Smaail, Draoui Nihed, Feron Olivier, Riant Olivier and Touzani Rachid, Library of Synthetic Compounds Based on Pyrazole Unit: Design and Screening Against Breast and Colorectal Cancer, Letters in Drug Design & Discovery 2014; 11 (8) . https://dx.doi.org/10.2174/1570180811666140512220842
DOI https://dx.doi.org/10.2174/1570180811666140512220842 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herbal Based Polymeric Nanoparticles as a Therapeutic Remedy for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry The Genus Glycosmis [Rutaceae]: A Comprehensive Review on its Phytochemical and Pharmacological Perspectives
The Natural Products Journal Recent Advancemnts in Biodegradable Ocular Implants
Current Drug Delivery QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Stem Cell and Regenerative Medicine
Current Stem Cell Research & Therapy Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Computed Tomographic Evaluation of Colonic Diverticulum Complications
Current Medical Imaging Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity
Mini-Reviews in Medicinal Chemistry Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Reducing the Burden of Cervical Cancer in the Developing World
Current Women`s Health Reviews